Overview

The global Non-Surgical Facial Rejuvenation Market was valued at USD 19.6 billion in 2025 and is projected to reach USD 43.2 billion by 2034, growing at a CAGR of 9.1% during the forecast period (2026–2034). The market growth is driven by rising demand for minimally invasive aesthetic procedures, growing preference for non-surgical anti-aging treatments, increasing adoption of injectables and energy-based technologies, expanding availability of aesthetic clinics and treatments. The market is shifting from single-modality wrinkle correction toward combination and regenerative treatment protocols that pair neuromodulators, biostimulatory fillers, and energy-based skin-tightening in a single treatment plan. Government initiatives such as the European Union's Medical Device Regulation (EU) 2017/745 and its Annex XVI common specifications (Regulation (EU) 2022/2346), which bring non-medical-purpose aesthetic devices including dermal fillers, cosmetic lasers and IPL systems under full medical-device compliance and mandatory EUDAMED registration through 2026, are raising quality and safety requirements across the region. North America is the dominating region, supported by a mature injectable and medspa infrastructure and high consumer willingness-to-pay, while Asia-Pacific is the fastest-growing region, driven by expanding dermatology and medical-aesthetics capacity in South Korea, China, Japan and India, a fast-growing base of domestically manufactured botulinum toxin and filler products, and rising outbound and inbound medical-aesthetics tourism across the region.

Market Size & Share

Market Dynamics

KEY MARKET TREND:

Regenerative and Biostimulatory Injectables Emerging as a Transformational Trend

• Aesthetic manufacturers are shifting product pipelines from single-purpose hyaluronic-acid fillers toward biostimulatory formulations (poly-L-lactic acid, calcium hydroxylapatite, and PDRN-based skin boosters) that stimulate the patient's own collagen production for longer-lasting, more natural-looking facial rejuvenation results.
• Providers are increasingly combining neuromodulators, biostimulatory fillers and energy-based skin-tightening devices within a single treatment plan, supported by AI-assisted facial mapping and digital treatment-visualization tools used to plan and communicate expected outcomes to patients.
• Demand for skin-quality-focused “skin booster” treatments is broadening beyond core hyaluronic-acid chemistry to include exosome and growth-factor technologies, as clinics diversify recurring-revenue treatment menus around skin hydration and texture rather than volume alone.
• Galderma expanded its Restylane Skinboosters product range across European and Asia-Pacific markets, reflecting rising international demand for clinically validated, hyaluronic-acid-based regenerative skin-booster treatments.

KEY MARKET DRIVER:

Rising Global Volume of Non-Surgical Aesthetic Procedures is the Key Driver

• Consumer acceptance of minimally invasive facial treatments continues to broaden across age groups, with plastic-surgery association data showing older adults recording the fastest growth in cosmetic procedure volumes as patients seek natural-looking, low-downtime rejuvenation rather than surgical intervention.
• Growing use of GLP-1 weight-loss medications is generating a distinct patient cohort seeking facial volume restoration and skin-tightening treatments to address rapid weight-loss-related facial skin laxity, expanding the addressable base for biostimulatory fillers and energy-based tightening devices.
• Expansion of dermatology clinics, medical spas and hospital-based aesthetic centers, together with growing numbers of trained injectors globally, is improving treatment access and supporting repeat-visit, subscription-style aesthetic care models.
• Government initiatives such as England’s Health and Care Act 2022, which enables licensing requirements for specified non-surgical cosmetic procedures and treatment premises, are strengthening safety and practitioner standards, supporting consumer confidence and the organized expansion of non-surgical facial rejuvenation services.

KEY MARKET OPPORTUNITY:

Expansion of Asia-Pacific Domestic Manufacturing and Medical-Aesthetics Infrastructure Creates Significant Opportunity

• Rapid build-out of dermatology and medical-aesthetics capacity across South Korea, China, Japan and India is opening new markets for both global and domestic injectable and device manufacturers, supported by a growing base of locally approved botulinum toxin and filler products.
• Rising domestic manufacturing capability in South Korea is enabling regional players to pursue regulatory approval in the United States, Europe and China simultaneously, creating opportunities for cost-competitive product entry into premium Western markets.
• Growing consumer interest in “prejuvenation” early, preventive non-surgical treatment among younger adults together with expanding male-grooming demand, is broadening the addressable patient base beyond the traditional core demographic.
• Research published in 2026 identified 15 Korean manufacturers and 19 registered botulinum toxin products domestically, reflecting South Korea's deepening manufacturing base and its growing role in supplying the global non-surgical facial rejuvenation market.

Non-Surgical Facial Rejuvenation Market Size, 2025–2034 (USD Billion)

Segmentation Analysis

Analysis by Treatment Type

Dermal fillers held the largest market share in 2025 because these treatments remain the most-performed, most clinically established, and most widely reimbursement-independent non-surgical aesthetic procedures globally. Their short in-office administration time, predictable and reversible (in the case of hyaluronic-acid fillers) results, and broad physician familiarity keep them the default entry point for new patients.

Biostimulators are projected to grow at the fastest CAGR during the forecast period as patients increasingly seek gradual, natural-looking improvements in skin hydration, elasticity and texture rather than volume correction alone. Rising clinical evidence supporting collagen-stimulating chemistries (poly-L-lactic acid, calcium hydroxylapatite, PDRN), combined with growing demand from post-weight-loss patients seeking skin-quality improvement, is broadening this segment's addressable base.

Treatment Type categories include

                ·           Dermal fillers (Dominating Segment)

                ·           Biostimulators (Highest CAGR Segment)

                ·           Chemical Peels

                ·           Thread Lifts

Analysis by Technology

Injectable-based technologies held the largest market share in 2025, supported by decades of clinical safety data, well-established reimbursement-independent cash-pay economics, and continuous product-pipeline investment from large pharmaceutical-aesthetics companies. Injectables remain the preferred entry treatment across nearly all regional markets due to short procedure time and predictable, physician-controlled dosing.

Device-based technologies are projected to grow at the fastest CAGR during the forecast period, driven by rising demand for non-invasive skin-tightening as an alternative to surgical facelifts, particularly among patients experiencing post-weight-loss skin laxity. Continuing innovation in radiofrequency microneedling, high-intensity focused ultrasound, and combination energy platforms is expanding the range of treatable indications and improving single-session efficacy, supporting faster segment growth than injectables.

Technology categories include

                ·           Injectable-Based (Dominating Segment)

                ·           Device-Based (Highest CAGR Segment)

                ·           Topical

Analysis by Application

Wrinkle reduction held the largest market share in 2025, as fine lines, glabellar lines, forehead lines and crow's feet remain the most commonly presented aesthetic concern across all major markets, sustained by high repeat-treatment frequency for neuromodulators and superficial fillers. The availability of multiple treatment options and shorter recovery times also encourages repeat visits and broader adoption of wrinkle-reduction procedures.

Skin tightening is projected to grow at the fastest CAGR during the forecast period, propelled by rising GLP-1-medication-related skin laxity, growing consumer preference for non-surgical alternatives to facelifts, and continuous innovation in ultrasound and radiofrequency-based lifting platforms such as Ultherapy PRIME and comparable systems.

Application categories include

                ·           Wrinkle Reduction (Dominating Segment)

                ·           Skin Tightening (Highest CAGR Segment)

                ·           Volume Restoration

                ·           Texture Improvement

                ·           Others

Analysis by End User

Dermatology clinics held the largest market share in 2025, supported by physician-led treatment protocols, higher patient trust in medically supervised procedures, and their role as the primary channel through which manufacturers launch and promote new injectable and device technologies. Regular follow-up consultations and repeat treatments also contribute to sustained patient volumes.

Medical spas are projected to grow at the fastest CAGR during the forecast period, as the medspa channel continues to expand rapidly in the United States and other developed markets, offering lower-cost, high-volume access to core injectable and energy-based treatments under physician-delegated supervision models. Expansion of treatment menus, promotional packages, and repeat-care programs is also contributing to higher patient volumes and visit frequency.

End User categories include

                ·           Dermatology Clinics (Dominating Segment)

                ·           Medical Spas (Highest CAGR Segment)

                ·           Hospitals

                ·           Home-Use 

By Region

Non-Surgical Facial Rejuvenation Market Regional Analysis

Non-Surgical Facial Rejuvenation Market Share 2025 (%)

North America

38%

South America

XX%

Europe

XX%

Middle East Africa

XX%

Asia Pacific

28%

Regional Analysis

North America held the largest market share in 2025, accounting for 38% of global market share, supported by a mature, high-spend medical-aesthetics infrastructure, deep dermatologist and plastic-surgeon density, and strong consumer willingness-to-pay for cash-pay cosmetic procedures. The United States dominates regional demand, driven by widespread medspa penetration, an established injectable-reimbursement-independent business model, and rapid adoption of new biostimulatory and energy-based technologies. Growing procedure volumes among adults aged 66 and above the fastest-growing age cohort by procedure volume according to 2025 plastic-surgery association data together with continued expansion of GLP-1-related skin-quality treatments, are reinforcing North America's leadership position. Canada is witnessing steady adoption of biostimulatory fillers and energy-based skin-tightening platforms alongside a growing medical-tourism inflow from neighboring markets.

Asia-Pacific is projected to grow at the fastest CAGR during the forecast period, driven by rapid expansion of dermatology and medical-aesthetics capacity across South Korea, China, Japan and India. South Korea has developed into a global center for botulinum toxin and filler manufacturing, with a growing base of domestically approved products increasingly securing regulatory approval in the United States, Europe and China. China represents a major growth opportunity as rising disposable income and increasing acceptance of aesthetic medicine expand the domestic patient base, while Japan's aging population continues to favor minimally invasive treatments over surgery. India is seeing rapid growth in dermatology-clinic and medspa infrastructure supported by rising urban disposable incomes and growing aesthetic awareness.

Countries and Regions Covered

North America (Dominating Region)

o    United States (Largest Country Market)

o    Canada

o    Mexico

Asia-Pacific (Fastest Growing Region)

o    South Korea (Largest Country Market)

o    China (Fastest-Growing Country Market)

o    Japan

o    India

o    Rest of Asia-Pacific

Europe

o    Germany (Largest Country Market)

o    United Kingdom

o    France

o    Italy

o    Rest of Europe

Latin America

o    Brazil (Largest Country Market)

o    Chile (Fastest-Growing Country Market)

o    Rest of Latin America

Middle East & Africa

o    Saudi Arabia (Largest Country Market)

o    United Arab Emirates (Fastest-Growing Country Market)

o    Rest of Middle East & Africa

Market Share

The market is consolidated in injectables, with leading companies including Galderma S.A., Merz Pharma GmbH & Co. KGaA, Teoxane Laboratories SA, Croma-Pharma GmbH, Medytox Inc., and Prollenium Medical Technologies Inc. competing through extensive clinical evidence, physician-education networks, and broad distribution capabilities. The energy-based device segment is comparatively more fragmented, with companies such as Cutera, InMode, BTL Industries, Sofwave Medical, Sciton, Fotona, CLASSYS, WONTECH, and Aerolase competing on technology differentiation across laser, radiofrequency, ultrasound, HIFU, and other energy-based modalities. Key success factors include regulatory approval breadth across the United States, European Union and China, physician-training infrastructure, clinical evidence supporting long-term safety and efficacy, and strength of direct-to-clinic distribution relationships. Leading companies are prioritizing biostimulatory and regenerative product pipelines, combination-therapy platforms, advanced energy-based treatment systems, and expanded international distribution to broaden treatment portfolios and strengthen market presence.

Key Players

           ·           Galderma S.A. (Switzerland)

           ·           Merz Pharma GmbH & Co. KGaA (Germany)

           ·           Teoxane Laboratories SA (Switzerland)

           ·           Croma-Pharma GmbH (Austria)

           ·           Medytox Inc. (South Korea)

           ·           Prollenium Medical Technologies Inc. (Canada)

           ·           Cutera, Inc. (United States)

           ·           InMode Ltd. (Israel)

           ·           BTL Industries s.r.o. (Czech Republic)

           ·           Sofwave Medical Ltd. (Israel)

           ·           Sciton Inc. (United States)

           ·           Fotona d.o.o. (Slovenia)

           ·           CLASSYS Inc. (South Korea)

           ·           WONTECH Co., Ltd. (South Korea)

           ·           Aerolase Corporation (United States)

Recent Market Developments

• January 2025: Teoxane Laboratories SA submitted a competing proposal to acquire Revance Therapeutics for USD 3.60 per share, a 16% premium to Crown Laboratories' prior offer, underscoring intensifying strategic interest in neuromodulator and filler assets ahead of Crown's completed acquisition the following month.
• February 2025: Crown Laboratories completed its USD 924 million acquisition of Revance Therapeutics, consolidating the DAXXIFY neuromodulator and RHA Collection dermal filler franchise into an expanded aesthetics portfolio and reinforcing the trend of pharmaceutical/specialty-consumer consolidation in facial injectables.
• August 2025: CLASSYS receives CE MDR certification for Ultraformer MPT. CLASSYS announced European CE MDR certification for its Ultraformer MPT HIFU system, supporting wider commercialization of non-invasive facial lifting and rejuvenation treatments across European markets.
• November 2026: The European Union's expanded EU MDR Annex XVI common-specification requirements moved toward mandatory EUDAMED registration deadlines for non-medical-purpose aesthetic devices including dermal fillers, cosmetic lasers and IPL systems tightening market-entry and post-market surveillance requirements for facial-aesthetic device manufacturers across Europe.

Frequently Asked Questions

Key Questions Answered

Request a Sample

1

What is Non-Surgical Facial Rejuvenation?

2

What is the CAGR of the Non-Surgical Facial Rejuvenation Market?

3

Which treatment type leads the Non-Surgical Facial Rejuvenation Market?

4

Which end user dominates the Non-Surgical Facial Rejuvenation Market?

5

Which technology segment has the highest market share?

6

What are the latest trends in the Non-Surgical Facial Rejuvenation Market?

7

Who are the end users of non-surgical facial rejuvenation treatments?

Why Choose IG Transformation

Speak to Analyst

Strong Industry Focus

Extensive Product Offerings

Customer Research Services

Robust Research Methodology

Comprehensive Reports

Latest Technological Developments

Value Chain Analysis

Potential Market Opportunities

Growth Dynamics

Quality Assurance

Post-sales Support

Regular Report Updates